Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03059498 · ClinicalTrials.gov registry record · Early Phase 1
PECS Block: Plasma Bupivacaine Level
A Early Phase 1 study of Nerve Blocks, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT03059498 is a Early Phase 1 study of Nerve Blocks that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 20 participants. The trial reports 1 study location across 1 state.
The verdict
NCT03059498, a Early Phase 1 study of Nerve Blocks, has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine peak plasma bupivacaine concentrations in a similar fashion for PECS I/II blocks. The investigators hypothesis is that the mean peak plasma levels for patients undergoing PECS I/II blocks will be less than the levels reported to cause early neurotoxicity of \[2.2 (0.9) micrograms/ml\]6 in patients receiving intravenous bupivacaine infusions.
Conditions Studied
Interventions
- DRUG Bupivacaine
- PROCEDURE Unilateral PECS I and II block
- PROCEDURE Bilateral PECS I and II block
Study Locations (1)
North Carolina
- Wake Forest Baptist Medical Center - Winston-Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2017-06-06 |
| Est. Completion | 2017-11-15 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03059498
The ClinicalTrials.gov registry entry for NCT03059498 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Nerve Blocks appearing as the primary indexed condition, and to 3 interventions - of which Bupivacaine is the first listed.
NCT03059498 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT03059498 about?
NCT03059498 is a clinical study titled "PECS Block: Plasma Bupivacaine Level". The purpose of this study is to determine peak plasma bupivacaine concentrations in a similar fashion for PECS I/II blocks. The investigators hypothesis is that the mean peak plasma levels for patients undergoing PECS I/II blocks will be less than the levels reported to cause early neurotoxicity of ...
What is the current status of trial NCT03059498?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 20 participants. The study started on 2017-06-06. Estimated completion is 2017-11-15.
What conditions does trial NCT03059498 study?
This clinical trial studies the following conditions: Nerve Blocks.
What interventions are being tested in trial NCT03059498?
The interventions under investigation include: Bupivacaine (DRUG), Unilateral PECS I and II block (PROCEDURE), Bilateral PECS I and II block (PROCEDURE).
Who is sponsoring clinical trial NCT03059498?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03059498 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.